Second Affiliated Hospital, Zhejiang University, School of Medicine — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Second Affiliated Hospital, Zhejiang University, School of Medicine appears in 212 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials212

Recruiting shown60

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLCNCT07823855 · lead sponsor · 2026-06-16

Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver InjuryNCT07760038 · lead sponsor · 2026-06-01

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast CancerNCT07616440 · lead sponsor · 2026-06-01

Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung AdenocarcinomaNCT07744529 · lead sponsor · 2026-05-28

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerNCT07616427 · lead sponsor · 2026-05-20

Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated CardiomyopathyNCT07516288 · lead sponsor · 2026-05-11

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerNCT07616453 · lead sponsor · 2026-05-06

Laparoscopic Versus Open Surgery for Colon Cancer With Visceral ObesityNCT07314996 · lead sponsor · 2026-01-18

the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast CancerNCT07380646 · lead sponsor · 2026-01-07

Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast CancerNCT07457359 · lead sponsor · 2026-01-04

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerNCT07340398 · lead sponsor · 2025-12-25

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus CyclophosphamideNCT07716176 · lead sponsor · 2025-12-12

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab DeruxtecanNCT07716189 · lead sponsor · 2025-12-12

Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial IntelligenceNCT07252986 · lead sponsor · 2025-12-01

Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab DeruxtecanNCT07537673 · lead sponsor · 2025-11-25

Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus CyclophosphamideNCT07537699 · lead sponsor · 2025-11-25

A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological MapsNCT07244094 · lead sponsor · 2025-11-15

Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental DisordersNCT07479758 · lead sponsor · 2025-11-01

The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung CancerNCT07617246 · lead sponsor · 2025-11-01

Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's DiseaseNCT07244640 · lead sponsor · 2025-11-01

A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid TumorsNCT07250386 · lead sponsor · 2025-10-13

Efficacy and Safety of iStent in Reducing Intraocular Pressure in Open-angle GlaucomaNCT07354009 · lead sponsor · 2025-10-07

A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast CancerNCT07304934 · lead sponsor · 2025-08-01

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerNCT07061535 · lead sponsor · 2025-07-30

Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan GranulesNCT07114120 · lead sponsor · 2025-07-14

A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLCNCT07193641 · lead sponsor · 2025-06-15

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityNCT07293325 · lead sponsor · 2025-06-02

Comparison of Sequential to Initial Combination Therapy in PAHNCT06968962 · lead sponsor · 2025-05-14

Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung CancerNCT06972576 · lead sponsor · 2025-05-09

Effect of Video Viewing on Intravitreal Injection ExperienceNCT07002372 · lead sponsor · 2025-05-05

Safety and Efficacy of FAP iCDC in End-stage Dilated CardiomyopathyNCT06902896 · lead sponsor · 2025-04-22

Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label TrialNCT06863532 · lead sponsor · 2025-03-30

Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast CancerNCT06964906 · lead sponsor · 2025-03-04

Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical TechniquesNCT06687408 · lead sponsor · 2025-03-01

Effects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate DepressionNCT06741540 · lead sponsor · 2025-01-01

Liposomal Irinotecan and Apatinib in ES-SCLCNCT06749691 · lead sponsor · 2024-12-28

Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast CancerNCT06671262 · lead sponsor · 2024-12-26

Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant ChemotherapyNCT06596018 · lead sponsor · 2024-12-25

Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant ChemotherapyNCT04744506 · lead sponsor · 2024-11-30

Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast CancerNCT06658080 · lead sponsor · 2024-11-09

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLCNCT06863506 · lead sponsor · 2024-10-01

Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung CancerNCT06523673 · lead sponsor · 2024-09-01

Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic ReconstructionNCT06464913 · lead sponsor · 2024-09-01

Prospective Observational Cohort Study of Moderate Aortic Valve DiseaseNCT06595992 · lead sponsor · 2024-09-01

A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT ImagingNCT07463300 · lead sponsor · 2024-08-01

Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With LecanemabNCT06741553 · lead sponsor · 2024-06-28

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast CancerNCT06587789 · lead sponsor · 2024-01-01

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast CancerNCT06155305 · lead sponsor · 2023-12-06

Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer PatientsNCT06023212 · lead sponsor · 2023-12-01

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High RisksNCT05212454 · lead sponsor · 2023-03-15

Prophylactic Irradiation to the Contralateral Breast for BCAs PatientsNCT04960839 · lead sponsor · 2023-01-01

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）NCT05429463 · lead sponsor · 2022-11-11

A Study for the Adjuvant Treatment of Breast CancerNCT05420467 · lead sponsor · 2022-07-10

A Study for the Neoadjuvant Treatment of Breast CancerNCT05420454 · lead sponsor · 2022-07-10

Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin RegimenNCT05731258 · lead sponsor · 2022-05-01

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's SyndromeNCT04981145 · lead sponsor · 2022-01-14

Clinical Study of Endocardial Myocardial BiopsyNCT05718128 · lead sponsor · 2021-06-01

China Longitudinal Aging and Cognitive Impairment StudyNCT05468905 · lead sponsor · 2021-01-10

Prospective Cohort Study of Intracerebral HemorrhageNCT04707105 · lead sponsor · 2020-12-29

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast CancerNCT04576143 · lead sponsor · 2020-09-20

Drugs studied in this sponsor's trials

44 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Second Affiliated Hospital, Zhejiang University, School of Medicine as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

trastuzumab6

carboplatin5

docetaxel5

pertuzumab5

cyclophosphamide4

epirubicin4

placebo4

paclitaxel protein-bound3

trastuzumab RxCUI 224905 · Lead sponsor in 6 linked trial(s) · 3 currently recruiting 6 trials carboplatin RxCUI 40048 · Lead sponsor in 5 linked trial(s) · 4 currently recruiting 5 trials docetaxel RxCUI 72962 · Lead sponsor in 4 linked trial(s) · 3 currently recruiting 5 trials pertuzumab RxCUI 1298944 · Lead sponsor in 5 linked trial(s) · 3 currently recruiting 5 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 3 linked trial(s) · 3 currently recruiting 4 trials epirubicin RxCUI 3995 · Lead sponsor in 3 linked trial(s) · 3 currently recruiting 4 trials placebo RxCUI 8375 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 3 linked trial(s) · 3 currently recruiting 3 trials bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials capecitabine RxCUI 194000 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials paclitaxel RxCUI 56946 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials tofacitinib RxCUI 1357536 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials ambrisentan RxCUI 358274 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial amlodipine RxCUI 17767 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial aprepitant RxCUI 358255 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial azilsartan RxCUI 1091643 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial azithromycin RxCUI 18631 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial budesonide / formoterol RxCUI 389132 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ensartinib RxCUI 2712546 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial etoposide RxCUI 4179 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial finerenone RxCUI 2562811 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fosaprepitant RxCUI 1731071 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fulvestrant RxCUI 282357 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gefitinib RxCUI 328134 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor174

collaborator38

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.